Advanced

The strategy of piking a target : What is aktually most effective?

Costa, Carlotta and Bosch, Ana LU (2018) In Clinical Cancer Research 24(9). p.2029-2031
Abstract

Breast and gynecologic cancers harboring PIK3CA mutations showed no significant responses to AZD5363, a pan-AKT catalytic inhibitor, in contrast with previous in vitro data showing activity of the drug in this subset of cancers. These results raise the question of how to select the most accurate predictive biomarkers of response.

Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Clinical Cancer Research
volume
24
issue
9
pages
3 pages
publisher
American Association for Cancer Research
external identifiers
  • scopus:85047831421
ISSN
1078-0432
DOI
10.1158/1078-0432.CCR-17-3440
language
English
LU publication?
yes
id
55abbf09-9561-4560-857f-1642bb585414
date added to LUP
2018-06-14 13:32:22
date last changed
2018-10-03 10:51:20
@article{55abbf09-9561-4560-857f-1642bb585414,
  abstract     = {<p>Breast and gynecologic cancers harboring PIK3CA mutations showed no significant responses to AZD5363, a pan-AKT catalytic inhibitor, in contrast with previous in vitro data showing activity of the drug in this subset of cancers. These results raise the question of how to select the most accurate predictive biomarkers of response.</p>},
  author       = {Costa, Carlotta and Bosch, Ana},
  issn         = {1078-0432},
  language     = {eng},
  month        = {05},
  number       = {9},
  pages        = {2029--2031},
  publisher    = {American Association for Cancer Research},
  series       = {Clinical Cancer Research},
  title        = {The strategy of piking a target : What is aktually most effective?},
  url          = {http://dx.doi.org/10.1158/1078-0432.CCR-17-3440},
  volume       = {24},
  year         = {2018},
}